Medical Condition News

RSS

Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH

Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.

17 Apr 2010

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.

From Santen Pharmaceutical Co., Ltd. 17 Apr 2010

New data on Cladribine Tablets presented at AAN annual meeting

EMD Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that new data providing further understanding on Cladribine Tablets as a potential new therapeutic option for relapsing forms of multiple sclerosis were presented at the 62nd Annual Meeting of the American Academy of Neurology.

17 Apr 2010

70% of COPD patients under-diagnosed due to lack of disease knowledge

"It is high time to demystify COPD in order to better explain the issues and help people who suffer from this disease," says Dr. Jean Bourbeau, Director of the Respiratory, Epidemiology and Clinical Research Unit at the Montreal Chest Institute of the MUHC, and lead investigator of CanCOLD along with Dr. Wan Tan of The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia.

17 Apr 2010

Treatment with high dose UDCA no more effective for NASH: German study

Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid is no more effective than placebo in the treatment of non-alcoholic steatohepatitis, the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver.

17 Apr 2010

Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL

In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp Neurosciences Inc. described further encouraging trends observed in a previously reported Phase 2 study of KNS-760704 (dexpramipexole) in ALS.

17 Apr 2010

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

Federal cancer research is 'at a breaking point,' IOM study finds

Bloomberg: "The government's cancer research network is 'approaching a state of crisis' as waste and inefficiency cause 40 percent of late-stage trials it funds to be abandoned before completion, according to a report released yesterday. The government-funded National Cancer Institute's clinical trials group isn't able to effectively study the benefits of new and current treatments, according to the analysis by the Institute of Medicine.

17 Apr 2010

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

17 Apr 2010

BioMers launches SimpliClear braces system and ASTICS Color retainers for orthodontic treatment

BioMers today announced the launch of two new aesthetic products for orthodontic treatment, the SimpliClear™ braces system and the ASTICS® Color retainers.

16 Apr 2010

Endra Life Sciences launches Nexus 128 preclinical photoacoustic CT scanner

Endra Life Sciences today announced the launch of the Nexus 128, a preclinical photoacoustic computed tomography (CT) scanner for small animal imaging. The system is used for simple, fast, non-invasive quantification of tumor vasculature and other physiological parameters for preclinical research.

16 Apr 2010

Victims of SCA treated with AEDs by bystanders have much greater chance of survival

Victims of sudden cardiac arrest who are treated with automated external defibrillators by bystanders have a much greater chance of survival than their counterparts, according to landmark research by the Resuscitation Outcomes Consortium, just published in the Journal of the American College of Cardiology.

16 Apr 2010

Research reveals TRPV3 protein as potential new drug target for cancer and skin disorders

New findings about a temperature sensor in the skin could lead to novel approaches to controlling excess hair growth and treating skin cancers.

16 Apr 2010

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

MinuteClinic helps patients take control of allergies with treatment services seven days a week

As trees blossom and shed their pollen and grasses and weeds germinate in yards and fields across America, allergy sufferers are retreating indoors with seemingly no relief in sight. MinuteClinic, the walk-in medical clinic inside select CVS/pharmacy stores, can help patients breathe easier and take control of their allergies this spring with treatment services available seven days a week, including weekday evening hours.

16 Apr 2010

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus and progression to cancers other than hepatocellular carcinoma.

16 Apr 2010

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

The socioeconomic status of a country has long been considered a potentially significant factor in the availability of high-quality health-care interventions and even a determinant of long-term patient outcomes. A new study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation reports that in Europe, socioeconomic factors have a direct correlation to the rates and outcomes of stem cell transplantation for patients with acute myeloid leukemia (AML).

16 Apr 2010

Serametrix announces commercial launch of serum test for measuring serum antibodies

Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments.

16 Apr 2010

AKI patients admitted to hospital on a weekend more likely to die: Study

Patients with acute kidney injury who are admitted to the hospital on a weekend are more likely to die than those admitted on a weekday, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. This disparity was most evident in smaller hospitals.

16 Apr 2010

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Type 1 diabetes is the most common cause of diabetes in children, although it may occur at any age. Also called juvenile diabetes, this pathology usually results from autoimmune destruction of insulin-producing cells of the pancreas.

16 Apr 2010

Medical Condition News

Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

New data on Cladribine Tablets presented at AAN annual meeting

70% of COPD patients under-diagnosed due to lack of disease knowledge

Treatment with high dose UDCA no more effective for NASH: German study

Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL

RegeneRx Biopharmaceuticals proposes common stock public offering

Federal cancer research is 'at a breaking point,' IOM study finds

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

BioMers launches SimpliClear braces system and ASTICS Color retainers for orthodontic treatment

Endra Life Sciences launches Nexus 128 preclinical photoacoustic CT scanner

Victims of SCA treated with AEDs by bystanders have much greater chance of survival

Research reveals TRPV3 protein as potential new drug target for cancer and skin disorders

VisEn Medical expands FMT imaging platform

MinuteClinic helps patients take control of allergies with treatment services seven days a week

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Serametrix announces commercial launch of serum test for measuring serum antibodies

AKI patients admitted to hospital on a weekend more likely to die: Study

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News